Olmesartan Medoxomil Tablet, Coated
NDC Package 71209-080-01
Package Information
Olmesartan Medoxomil tablets is olmesartan is used to treat high blood pressure (hypertension). This formulation utilizes a tablet, coated delivery system. Marketed by Cadila Pharmaceuticals Limited, this product is identified by NDC 71209-080 and is authorized under FDA application ANDA210682.
Identification & Billing
- RxCUI: 349373 - olmesartan medoxomil 5 MG Oral Tablet
- RxCUI: 349401 - olmesartan medoxomil 20 MG Oral Tablet
- RxCUI: 349405 - olmesartan medoxomil 40 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71209 - Cadila Pharmaceuticals Limited
- 71209-080 - Olmesartan Medoxomil
- 71209-080-01 - 30 TABLET, COATED in 1 BOTTLE
- 71209-080 - Olmesartan Medoxomil
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (71209-080). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71209-080-01 identifies a specific commercial package of 30 tablet, coated in 1 bottle of Olmesartan Medoxomil, a human prescription drug labeled by Cadila Pharmaceuticals Limited. This tablet, coated is formulated for oral use and contains olmesartan medoxomil as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cadila Pharmaceuticals Limited on January 01, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Olmesartan is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Olmesartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily.
How is this Cadila Pharmaceuticals Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71209008001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.